These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24790627)

  • 1. High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective.
    Yoshioka Y; Suzuki O; Otani Y; Yoshida K; Nose T; Ogawa K
    J Contemp Brachytherapy; 2014 Mar; 6(1):91-8. PubMed ID: 24790627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer.
    Yoshioka Y; Yoshida K; Yamazaki H; Nonomura N; Ogawa K
    J Radiat Res; 2013 Sep; 54(5):781-8. PubMed ID: 23543798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose-rate brachytherapy as monotherapy for prostate cancer.
    Demanes DJ; Ghilezan MI
    Brachytherapy; 2014; 13(6):529-41. PubMed ID: 25085454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
    Martinez AA; Demanes J; Vargas C; Schour L; Ghilezan M; Gustafson GS
    Am J Clin Oncol; 2010 Oct; 33(5):481-8. PubMed ID: 19952715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
    Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
    Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: a dose reduction trial.
    Yoshioka Y; Konishi K; Suzuki O; Nakai Y; Isohashi F; Seo Y; Otani Y; Koizumi M; Yoshida K; Yamazaki H; Nonomura N; Ogawa K
    Radiother Oncol; 2014 Jan; 110(1):114-9. PubMed ID: 24183062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study.
    Parry MG; Nossiter J; Sujenthiran A; Cowling TE; Patel RN; Morris M; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1219-1229. PubMed ID: 33279595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
    King CR
    Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brachytherapy: current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy?
    Morton GC; Hoskin PJ
    Clin Oncol (R Coll Radiol); 2013 Aug; 25(8):474-82. PubMed ID: 23727431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
    Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
    Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer.
    Potharaju M; Subramanaiam R; Venkataraman M; Perumal K; Ramakrishnan B; Vangara R; Reddy S
    Cureus; 2015 Aug; 7(8):e303. PubMed ID: 26430577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?
    Zaorsky NG; Doyle LA; Hurwitz MD; Dicker AP; Den RB
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):39-50. PubMed ID: 24124755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer.
    Parzen JS; Ye H; Gustafson G; Yan D; Martinez A; Chen PY; Ghilezan M; Sebastian E; Limbacher A; Krauss DJ
    Radiother Oncol; 2020 Jun; 147():123-129. PubMed ID: 32276193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
    Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
    Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.
    Demanes DJ; Martinez AA; Ghilezan M; Hill DR; Schour L; Brandt D; Gustafson G
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1286-92. PubMed ID: 21310546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions.
    Yoshioka Y; Konishi K; Sumida I; Takahashi Y; Isohashi F; Ogata T; Koizumi M; Yamazaki H; Nonomura N; Okuyama A; Inoue T
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):469-75. PubMed ID: 20646858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Brachytherapy for prostate cancer: high dose rate or low-dose rate?].
    Cosset JM; Haie-Meder C
    Cancer Radiother; 2005 Dec; 9(8):610-9. PubMed ID: 16226473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
    Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
    Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.